CG-0255 is a revolutionary new generation antiplatelet drug targeting P2Y12 receptor.  It is world’s first non-disulfide thiol based prodrug that replies only on esterases for one-step, fast and uniform hydrolytic activation.  It is also world’s first irreversible P2Y12 antagonist for IV injection.  CG-0255 is expected to be approved for percutaneous coronary intervention (PCI), perioperative antiplatelet therapy, perioperative antiplatelet therapy for mechanical thrombectomy in stroke.  CG-0255 fulfils unmet medical needs and can be applied broadly to address various clinical shortcomings.

CG-0255 is a revolutionary new generation antiplatelet drug targeting P2Y12 receptor.  It is world’s first non-disulfide thiol based prodrug that replies only on esterases for one-step, fast and uniform hydrolytic activation.  CG-0255 has been shown to have good dose linearity, minimal individual PK/PD variation in human, and excellent balance between antiplatelet effect and bleeding risk.  CG-0255 is expected to be approved through a special and expedited regulatory process for long term treatment of acute coronary syndrome (ACS), myocardial infarction (MI), stroke, and peripheral arterial disease (PAD).